CND-Dox-TF (720456)

CND-Dox-TF (also known as CDT) is an experimental nanoparticle-drug conjugate designed for the targeted delivery of doxorubicin to malignant cells overexpressing the transferrin receptor 1 (TFR1/CD71). The therapeutic consists of a carbon-nitride dot (CND) scaffold covalently linked to doxorubicin (Dox) and holo-transferrin (TF). The transferrin component acts as a targeting ligand, facilitating clathrin-mediated endocytosis upon binding to TFR1, a receptor frequently upregulated in aggressive cancers such as diffuse large B-cell lymphoma (DLBCL). Once internalized, the doxorubicin payload is released and translocates to the nucleus, where it induces double-stranded DNA breaks and apoptosis. In preclinical models, CDT has demonstrated significantly higher potency than unconjugated doxorubicin and has been evaluated as a component of the 'R-nanoCHOP' regimen (replacing standard doxorubicin in R-CHOP), showing improved overall survival and reduced systemic toxicities, particularly cardiotoxicity and myelosuppression.

Other names

CND-DoxCarbon-Nitride Dot-Doxorubicin-Transferrin